대장암 치료제 시장 규모, 점유율, 성장 분석, 약제 클래스별, 암 유형별, 유통 채널별, 지역별 - 산업 예측(2024-2031년)

Global Colorectal Cancer Therapeutics Market size was valued at USD 11.6 billion in 2022 and is poised to grow from USD 12.17 billion in 2023 to USD 17.84 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2024-2031).

The global colorectal cancer therapeutics market is experiencing robust growth driven by an alarming rise in the incidence of the disease, largely due to sedentary lifestyles, unhealthy dietary choices, and an increasingly aging population. The implementation of advanced diagnostic and screening techniques has facilitated early detection, enabling timely therapeutic interventions. Additionally, the market is significantly bolstered by innovations in cancer treatment, including targeted therapies, immunotherapies, and combination approaches that enhance treatment efficacy and improve patient outcomes while minimizing side effects. However, the landscape is not without challenges; the high costs associated with advanced cancer therapies present a substantial burden on healthcare systems, leading to potential inequities in access across different regions. Furthermore, the emergence of drug resistance complicates treatment efficacy over time, posing significant hurdles in achieving long-term remission for patients. Regulatory obstacles and intricate reimbursement systems also pose barriers, as stringent drug approval processes and variable reimbursement policies can restrict the accessibility of advanced therapies. Despite these hurdles, the US colorectal cancer therapeutics market is poised for sustainable growth, anticipated to achieve a steady compound annual growth rate (CAGR) in the upcoming forecast period, signaling a continued demand for innovative solutions in the fight against colorectal cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Colorectal Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Colorectal Cancer Therapeutics Market Segmental Analysis

Global Colorectal Cancer Therapeutics Market is segmented by Drug Class, Cancer Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Chemotherapy, Immunotherapy, and Others. Based on Cancer Type, the market is segmented into Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Colorectal Cancer Therapeutics Market

The Global Colorectal Cancer Therapeutics market is significantly driven by a surge in awareness campaigns and comprehensive screening programs aimed at fostering early detection and diagnosis of colorectal cancer. As public health initiatives emphasize the importance of timely intervention, patients are increasingly accessing screenings that facilitate early identification of cancer, leading to improved treatment outcomes. This heightened awareness not only empowers individuals to seek appropriate medical care but also elevates the demand for innovative and effective therapeutics, as healthcare providers focus on optimizing treatment strategies for patients diagnosed at earlier stages of the disease. Consequently, this growing emphasis on early detection is a critical market driver.

Restraints in the Global Colorectal Cancer Therapeutics Market

A significant market restraint for the global colorectal cancer therapeutics market is the phenomenon of drug resistance that colorectal cancer cells can develop over time. This resistance diminishes the effectiveness of existing treatments, resulting in treatment failures and disease progression, which ultimately hampers patient survival rates. The challenge of overcoming this resistance complicates treatment protocols and necessitates the continuous development of new therapies, contributing to increased research and development costs. As a result, healthcare providers and pharmaceutical companies may face reduced treatment options and higher financial burdens, which can limit market growth and patient access to effective colorectal cancer therapeutics.

Market Trends of the Global Colorectal Cancer Therapeutics Market

The Global Colorectal Cancer Therapeutics market is witnessing a notable trend towards the rising popularity of combination therapies. These innovative treatment approaches, which integrate chemotherapy, targeted therapy, and immunotherapy, are being increasingly explored for their ability to enhance therapeutic efficacy. By leveraging the synergistic effects of multiple modalities, combination therapies can significantly improve response rates, effectively tackle drug resistance, and ultimately prolong survival rates among colorectal cancer patients. This trend reflects a shift in treatment paradigms, as healthcare providers and researchers aim for more personalized, effective solutions in managing colorectal cancer, positioning combination therapies as a cornerstone in future therapeutic strategies.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Colorectal Cancer Therapeutics Market by Drug Class

• Market Overview
• Chemotherapy
• Immunotherapy
• Others

Colorectal Cancer Therapeutics Market by Cancer Type

• Market Overview
• Colorectal Adenocarcinoma
• Gastrointestinal Carcinoid Tumors
• Others

Colorectal Cancer Therapeutics Market byDistribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Colorectal Cancer Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Amgen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lilly (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncolytics Biotech Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Halozyme Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments